Schmidt Science Fellow @ Mass General Hospital | Harvard Medical School | Broad Institute (Vazquez-Garcia lab). Quantitative genomics for cancer evolution.
Boston, Massachusetts
Joined May 2023
- Tweets64
- Following191
- Followers283
- Likes163
Kit Gallagher retweeted
What does an Oxford mathematical biologist specialising in modelling cancer treatments do after completing their PhD? Why, go and do research at medical school, of course.
Kit Gallagher, Schmidt Science Fellow at Harvard Medical School, is your man.
Kit Gallagher retweeted
September is #OvarianCancer Awareness Month. At the @MoffittNews Nikon Center of Excellence, we’re tackling ovarian cancer by creating 3D tumor “patient avatars” outside of the body.
These models preserve the tumor microenvironment, helping us study drug responses and guide more personalized treatments.
Special thanks to collaborators @ErinGeorgeMD, @RMWenham, @MoffittGYNONC, @NikonInst.
Kit Gallagher retweeted
Save the date #MathOnco25! October 29th-31st in Tampa, Florida. Directly before the 13th @imoworkshop (November 3rd-7th) - stay the weekend and brainstorm the beaches! More information to follow but @EvolTherapy will be a key theme @mathonco @MoffittNews
Kit Gallagher retweeted
Authors Kit Gallagher, Maximillian Strobi, and Alexander Anderson at #AACR25. Read their article selected for the AI and Data Science Collection: Mathematical Model-Driven Deep Learning Enables Personalized Adaptive Therapy brnw.ch/21wSkvz
Kit Gallagher retweeted
From #AACR25, Alexander Anderson, PhD (@ara_anderson) and Kit Gallagher (@SciKit_G) discuss using a mathematical biomarker to predict treatment outcomes from adaptive therapy. #MoffittAACR25
Kit Gallagher retweeted
Why does this heterogeneity occur in adaptive therapy, and is a 'one-size-fits-all' protocol best for patients across this spectrum of responses?
Join Kit Gallagher (@SciKit_G) at #AACR25 as he shares a new mathematical biomarker that can be used to predict treatment outcomes from adaptive therapy.
Read more: abstractsonline.com/pp8/#!/2…
#MoffittAACR25
Kit Gallagher retweeted
Two wheels good.
'Make yourself useful' is one of those English phrases that frustrated parents might bark at their kids. But sometimes it is directed at mathematicians. @SciKit_G is more than up to the task.
Kit Gallagher retweeted
With just over 2 weeks until the 12th @imoworkshop I'm excited to share the artwork for the Toxicity focus! As always the brilliant @jillagal drove this grunge influenced innovation with help from @cgatenbee. Can you spot the other influence? @mathonco @MoffittNews #MoffittIMO
Kit Gallagher retweeted
Excited to announce that registration for the 12th
@mathonco workshop on Treatment Toxicity is now open. Held onsite @MoffittNews Nov 3-Nov 8 #MoffittIMO more details: imo12.eventbrite.com. Deluxe travel awards are available on a competitive basis, apply by 09/30!
Kit Gallagher retweeted
This week in #MathOnco 303:
Spatial landscapes, tumor organoids, neural-ODE's, drug tolerance, and more...
Art: Maximilian Strobl (@StroblMAR), Kit Gallagher (@SciKit_G), Jeffrey West (@mathoncbro), Jill Gallaher (@jillagal), Mark Robertson-Tessi (@markrt_), Sandy Anderson (@ara_anderson) 😎💯
Kit Gallagher retweeted
Interested in the evolution of drug resistance? Or working with animal models & clinical data to implement new a @EvolTherapy for NSCLC? The #AndersonLab is hiring a postdoc to work in @mathonco on our @NCIsysbio U54: The Delta Ecology of NSCLC. More here: labpages.moffitt.org/anderso…
Kit Gallagher retweeted
This remarkable study essentially validated our earlier finding in ALK+ NSCLC with @RobertVanderVe1 and @CancerConnector that resistance is acquired through a trajectory rather than a switch nature.com/articles/s41467-0….
Published today! We found that cancer cells adapting to drug treatments don't simply switch from a sensitive to resistant state; instead there's a ‘resistance continuum’ of resistant phenotypes with epigenetically reprogrammed states. 🧵⬇️
nature.com/articles/s41586-0… @Gustavo_SFranca
Kit Gallagher retweeted
I think this is a really cool study: evolution and heterogeneity predict long-term outcomes in prostate cancer. Worth emphasising that the lab team were blinded to clinical outcomes until a final great reveal: no risk of over-fitting here! Congrats @AndreaSottoriva and team
Does cancer #evolution & intra-tumour heterogeneity predict long-term relapse? We tested the evolutionary paradigm in prostate cancer clinical trials with long follow-up, combining genomics with digital histopathology: nature.com/articles/s43018-0…
Kit Gallagher retweeted
I'm not sure if I dreamed the conference dinner or not...what just happened? #SMB2024
Kit Gallagher retweeted
OK, I'm going to do it.
Live cancer immunology modeling in my @KSMB_SMB2024 talk on Friday, 2pm
MS041-IMMU-F1 (Room 218)
I'll use our new modeling language to build a quick @PhysiCell cancer-macrophage-T cell model in 5 minutes, or your money back. @SMB_MathBiology #smb2024
Kit Gallagher retweeted
Join Moffitt’s Gosia Weh (@gosia_handle) tomorrow at #SMB2024 for a discussion on cancer adaptation to treatment and mutation during the minisymposia session.
⏰: 7/4 from 4-5:40 p.m. KST
📍: #218(2F)
Learn more ➡️ bit.ly/4eEEOdk
Kit Gallagher retweeted
Tomorrow at #SMB2024: Kit Gallagher (@SciKit_G) presents the latest in personalized cancer treatments using mathematical modeling at the minisymposia session.
⏰: 7/1 from 4-5:40 p.m. KST
📍: #221(2F)
Learn more ➡️ bit.ly/3VK6HIv
Kit Gallagher retweeted
Chuffed to see our artwork make the @CellSystemsCP cover! Really fun collab with @SciKit_G, @ara_anderson,@mathoncbro,@jillagal and @markrt_. The strands are model sims (height=tumor size; shading=drug dose; s1=modulation; s2=skipping), arranged as a PARPi-inflicted DNA break.
This Post is from an account that no longer exists. Learn more
Kit Gallagher retweeted
New in Convergence Science from the June 1 issue—
Mathematical Model–Driven Deep Learning Enables Personalized Adaptive Therapy, by @SciKit_G, @ara_anderson et al.
bit.ly/4ecMHqu
@mathonco @MoffittNews #MathOnco #openaccess
